These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 37149104)

  • 41. Defining Patient Centric Pharmaceutical Drug Product Design.
    Stegemann S; Ternik RL; Onder G; Khan MA; van Riet-Nales DA
    AAPS J; 2016 Sep; 18(5):1047-1055. PubMed ID: 27317470
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Texture analysis - A versatile tool for pharmaceutical evaluation of solid oral dosage forms.
    Bogdan C; Hales D; Cornilă A; Casian T; Iovanov R; Tomuță I; Iurian S
    Int J Pharm; 2023 May; 638():122916. PubMed ID: 37019322
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evidence of acceptability of oral paediatric medicines: a review.
    Mistry P; Batchelor H;
    J Pharm Pharmacol; 2017 Apr; 69(4):361-376. PubMed ID: 27524471
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Use of computer decision support interventions to improve medication prescribing in older adults: a systematic review.
    Yourman L; Concato J; Agostini JV
    Am J Geriatr Pharmacother; 2008 Jun; 6(2):119-29. PubMed ID: 18675770
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Buccal Dosage Forms: General Considerations for Pediatric Patients.
    Montero-Padilla S; Velaga S; Morales JO
    AAPS PharmSciTech; 2017 Feb; 18(2):273-282. PubMed ID: 27301872
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pediatric drug formulations: a review of challenges and progress.
    Ivanovska V; Rademaker CM; van Dijk L; Mantel-Teeuwisse AK
    Pediatrics; 2014 Aug; 134(2):361-72. PubMed ID: 25022739
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Consensus guidelines for oral dosing of primarily renally cleared medications in older adults.
    Hanlon JT; Aspinall SL; Semla TP; Weisbord SD; Fried LF; Good CB; Fine MJ; Stone RA; Pugh MJ; Rossi MI; Handler SM
    J Am Geriatr Soc; 2009 Feb; 57(2):335-40. PubMed ID: 19170784
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Paediatric specific dosage forms: Patient and formulation considerations.
    Khan D; Kirby D; Bryson S; Shah M; Rahman Mohammed A
    Int J Pharm; 2022 Mar; 616():121501. PubMed ID: 35092832
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Overview of drug product development.
    Narayan P
    Curr Protoc Pharmacol; 2011 Dec; Chapter 7():Unit 7.3.1-29. PubMed ID: 22147349
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Orodispersible dosage forms: biopharmaceutical improvements and regulatory requirements.
    Cilurzo F; Musazzi UM; Franzé S; Selmin F; Minghetti P
    Drug Discov Today; 2018 Feb; 23(2):251-259. PubMed ID: 29030242
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Recent advances in pharmaceutical dosage forms and devices using additive manufacturing technologies.
    Gioumouxouzis CI; Karavasili C; Fatouros DG
    Drug Discov Today; 2019 Feb; 24(2):636-643. PubMed ID: 30503803
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Methodology Used to Assess Acceptability of Oral Pediatric Medicines: A Systematic Literature Search and Narrative Review.
    Mistry P; Batchelor H;
    Paediatr Drugs; 2017 Jun; 19(3):223-233. PubMed ID: 28413843
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Basics of Compounding: Clinical Pharmaceutics, Part 2.
    Allen LV
    Int J Pharm Compd; 2016; 20(6):485-493. PubMed ID: 28339388
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Optimal medication use in elders. Key to successful aging.
    Monane M; Monane S; Semla T
    West J Med; 1997 Oct; 167(4):233-7. PubMed ID: 9348752
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Patient centric formulations for paediatrics and geriatrics: Similarities and differences.
    Hanning SM; Lopez FL; Wong IC; Ernest TB; Tuleu C; Orlu Gul M
    Int J Pharm; 2016 Oct; 512(2):355-359. PubMed ID: 26976504
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vitro-in vivo correlation for complex non-oral drug products: Where do we stand?
    Shen J; Burgess DJ
    J Control Release; 2015 Dec; 219():644-651. PubMed ID: 26419305
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pediatric drug development: formulation considerations.
    Ali AA; Charoo NA; Abdallah DB
    Drug Dev Ind Pharm; 2014 Oct; 40(10):1283-99. PubMed ID: 24483293
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Swallowing dysfunction and dysphagia is an unrecognized challenge for oral drug therapy.
    Stegemann S; Gosch M; Breitkreutz J
    Int J Pharm; 2012 Jul; 430(1-2):197-206. PubMed ID: 22525080
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Patient Centric Pharmaceutical Drug Product Design-The Impact on Medication Adherence.
    Menditto E; Orlando V; De Rosa G; Minghetti P; Musazzi UM; Cahir C; Kurczewska-Michalak M; Kardas P; Costa E; Sousa Lobo JM; Almeida IF
    Pharmaceutics; 2020 Jan; 12(1):. PubMed ID: 31947888
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Parameters to consider for successful medication use in older adults - An AGePOP review.
    Hummler H; Sarwinska D; Weitschies W; Gollasch M; Page S
    Eur J Pharm Sci; 2023 Aug; 187():106453. PubMed ID: 37149104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.